PROTEOMICS Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PROTEOMICS

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who started this subject	6/10/2002 6:24:20 AM
From: nigel bates	Read Replies (1) of 539

CAMBRIDGE, U.K., June 10, 2002 (PRIMEZONE) -- Astex Technology, the U.K. structure-based drug discovery company today announced a structural biology research agreement with Mitsubishi Pharma Corporation to facilitate the rapid design and development of drug candidates. The collaboration will focus on solving novel human cytochrome P450 crystal structures that will be used in optimization of Mitsubishi's compounds, and so provide greater potential for their clinical success. Under the terms of the agreement, Astex will apply its proprietary X-ray crystallography technologies to obtain crystal structures of cytochrome P450s complexed to Mitsubishi's compounds. Financial details were not disclosed. Timothy Haines, Chief Executive of Astex commented: ``We are very pleased that Mitsubishi has chosen to work with Astex in this drug discovery program. The collaboration provides further validation of Astex's structure-based drug discovery technologies, and builds on our recent success in solving the first 3-dimensional crystal structure of a human cytochrome P450 enzyme.''

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next